AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

In a note released Monday, Cantor said that a "major overhang" has been removed for Bristol Myers's (BMY) new schizophrenia drug Cobenfy. Bristol Myers's "biggest competitive threat in ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales projections for the company’s new schizophrenia therapy Cobenfy following a ...

However, this came as good news for investors in AbbVie’s peer Bristol Myers Squibb (NYSE:BMY) as the company recently secured the U.S. FDA approval for its schizophrenia drug Cobenfy ...

Psychosis caused by these and other drugs is classified in the DSM-5 as "Substance ... or dialectical behavioral therapy (DBT). Cobenfy is a new treatment for schizophrenia used to improve positive ...

That’s according to a new report from Leerink Partners ... to the FDA approval of the companies’ landmark schizophrenia treatment Cobenfy. Behind BMS, Merck faces the next greatest threat ...

Boston-based Seaport said the money would support a pipeline of improved neuropsychiatric drug ... Cobenfy (xanomeline tartrate/trospium chloride), which became the first advance in schizophrenia ...